EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

Research output: Contribution to journalArticlepeer-review


  • Alberto F Sobrero
  • Joan Maurel
  • Louis Fehrenbacher
  • Werner Scheithauer
  • Yousif A Abubakr
  • Manfred P Lutz
  • M Eugenia Vega-Villegas
  • Cathy Eng
  • Ernst U Steinhauer
  • Jana Prausova
  • Heinz-Josef Lenz
  • Christophe Borg
  • Hendrik Kröning
  • Gabriele Luppi
  • Oliver Kisker
  • Angela Zubel
  • Christiane Langer
  • Justin Kopit
  • Howard A Burris

Colleges, School and Institutes


To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.


Original languageEnglish
Pages (from-to)2311-9
Number of pages9
JournalJournal of Clinical Oncology
Issue number14
Publication statusPublished - 2008